Delaware Investments Minnesota Municipal Income Fund II, Inc. (VMM) Reaches $13.04 Formed H&S; Durect (DRRX) Sellers Increased By 19.94% Their Shorts

DURECT Corporation (NASDAQ:DRRX) Logo

Durect Corporation (NASDAQ:DRRX) had an increase of 19.94% in short interest. DRRX’s SI was 3.93M shares in December as released by FINRA. Its up 19.94% from 3.27M shares previously. With 920,700 avg volume, 4 days are for Durect Corporation (NASDAQ:DRRX)’s short sellers to cover DRRX’s short positions. The stock decreased 6.14% or $0.135 during the last trading session, reaching $2.065. About 345,116 shares traded. DURECT Corporation (NASDAQ:DRRX) has declined 32.90% since December 4, 2018 and is downtrending. It has underperformed by 32.90% the S&P500. Some Historical DRRX News: 02/05/2018 – Durect 1Q Loss $8.3M; 19/03/2018 – Pain Therapeutics Announces FDA Advisory Committee Meeting for Remoxy ER; 09/05/2018 – DURECT CORP – EACH PARTY, PURSUANT TO AMENDMENT, IS ALSO PERMITTED TO DEVELOP OR COMMERCIALIZE COMPETING PRODUCTS; 09/05/2018 – DURECT Is Now Eligible for Up to $30 M in Milestone Payments Based on NDA Approval; 20/03/2018 – DURECT Announces FDA Advisory Committee Meeting For REMOXY(R) ER; 19/03/2018 – Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY ER®; 19/04/2018 – DJ DURECT Corporation, Inst Holders, 1Q 2018 (DRRX); 09/05/2018 – Sandoz Agreed to Pay DURECT a Tiered Double-Digit Royalty on Pdt Sales for Defined Period; 09/05/2018 – DURECT CORP – DURECT HAS RIGHT TO TERMINATE FOR CONVENIENCE PRIOR TO NDA APPROVAL; 20/03/2018 – DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER

Delaware Investments Minnesota Municipal Income Fund II, Inc. (VMM) formed H&S with $12.13 target or 7.00% below today’s $13.04 share price. Delaware Investments Minnesota Municipal Income Fund II, Inc. (VMM) has $149.98 million valuation. The stock increased 0.28% or $0.04 during the last trading session, reaching $13.04. About 6,768 shares traded. Delaware Investments Minnesota Municipal Income Fund II, Inc. (NYSE:VMM) has risen 6.42% since December 4, 2018 and is uptrending. It has outperformed by 6.42% the S&P500.

Investors sentiment increased to 1.12 in Q2 2019. Its up 0.45, from 0.67 in 2019Q1. It increased, as 25 investors sold DURECT Corporation shares while 20 reduced holdings. 16 funds opened positions while 14 raised stakes. 61.10 million shares or 13.33% less from 70.49 million shares in 2019Q1 were reported. Lmr Llp reported 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). First Eagle Mgmt Limited Company accumulated 0.04% or 22.48M shares. Bancorp Of Montreal Can owns 194 shares. Renaissance Tech Lc holds 0% in DURECT Corporation (NASDAQ:DRRX) or 3.21M shares. Ingalls & Snyder reported 0.26% of its portfolio in DURECT Corporation (NASDAQ:DRRX). Savings Bank Of America Corp De accumulated 675,130 shares. Credit Suisse Ag holds 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX) for 33,660 shares. Bnp Paribas Arbitrage reported 18,187 shares or 0% of all its holdings. Wells Fargo Mn holds 0% in DURECT Corporation (NASDAQ:DRRX) or 163,233 shares. Davenport Llc holds 0% or 591,520 shares. Cetera Advsr Lc accumulated 10,000 shares. Fincl Bank Of Mellon owns 0% invested in DURECT Corporation (NASDAQ:DRRX) for 96,124 shares. Proshare Advisors Ltd Liability Company has invested 0% in DURECT Corporation (NASDAQ:DRRX). Ameriprise Inc reported 0% in DURECT Corporation (NASDAQ:DRRX). Tower Cap Llc (Trc) stated it has 60,829 shares.

Among 2 analysts covering Durect (NASDAQ:DRRX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Durect has $500 highest and $2.1000 lowest target. $3.55’s average target is 71.91% above currents $2.065 stock price. Durect had 5 analyst reports since September 6, 2019 according to SRatingsIntel. Cantor Fitzgerald reinitiated DURECT Corporation (NASDAQ:DRRX) on Monday, November 18 with “Overweight” rating. The stock of DURECT Corporation (NASDAQ:DRRX) has “Hold” rating given on Wednesday, September 18 by Stifel Nicolaus.

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company has market cap of $397.23 million. The firm offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. It currently has negative earnings. The Company’s product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival.

DURECT Corporation (NASDAQ:DRRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.